Barchart.com
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
1.3200 x 5 1.4000 x 21
Post-market by (Cboe BZX)
1.3800 +0.0200 (+1.47%) 04/24/25 [NASDAQ]
1.3200 x 5 1.4000 x 21
Post-market 1.3800 unch (unch) 16:00 ET
News & Headlines for Thu, Apr 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs Quiver Quantitative, Inc. - Tue Dec 10, 2024

LAVA Therapeutics shifts focus to LAVA-1266, discontinues LAVA-1207, and secures $5 million from Johnson & Johnson.Quiver AI SummaryLAVA Therapeutics N.V. has announced a strategic reprioritization of...

LVTX : 1.3800 (+1.47%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments FinancialNewsMedia - Tue Mar 5, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 0.5833 (+2.95%)
OCEA : 0.0098 (-52.20%)
MRK : 79.84 (+1.40%)
ABBV : 180.37 (+1.88%)
ONC.TO : 0.81 (+2.53%)
LVTX : 1.3800 (+1.47%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments GlobeNewswire - Tue Mar 5, 2024

ONCY : 0.5833 (+2.95%)
MRK : 79.84 (+1.40%)
ABBV : 180.37 (+1.88%)
ONC.TO : 0.81 (+2.53%)
LVTX : 1.3800 (+1.47%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223 Spotlight Growth - Mon Sep 26, 2022

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

SGEN : 228.74 (-0.07%)
LVTX : 1.3800 (+1.47%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors Business Wire - Mon Sep 26, 2022

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 228.74 (-0.07%)
LVTX : 1.3800 (+1.47%)
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients Globe Newswire - Thu Jun 16, 2022

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at...

LVTX : 1.3800 (+1.47%)
LAVA Therapeutics Announces Two Appointments to its Board of Directors Globe Newswire - Wed Jun 15, 2022

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies...

LVTX : 1.3800 (+1.47%)
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Wed Jun 1, 2022

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. ...

LVTX : 1.3800 (+1.47%)
LAVA Therapeutics Announces Annual Meeting of Shareholders Globe Newswire - Tue May 31, 2022

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage...

LVTX : 1.3800 (+1.47%)
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results Globe Newswire - Tue May 17, 2022

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple...

LVTX : 1.3800 (+1.47%)

Barchart Exclusives

1 ‘Strong Buy’ Dividend Stock to Buy for an ‘America First’ World Barchart - 1 hour ago
GE Aerospace is emerging as a top “Strong Buy” dividend stock, with an 11% jump in revenue and a nearly $1 billion investment in U.S. manufacturing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot